135 related articles for article (PubMed ID: 33438100)
1. Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT.
Hotta M; Minamimoto R; Toyohara J; Nohara K; Nakajima K; Takase K; Yamada K
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2615-2623. PubMed ID: 33438100
[TBL] [Abstract][Full Text] [Related]
2. Influence of volumetric 4'-[methyl-
Hoshikawa H; Mori T; Maeda Y; Takahashi S; Ouchi Y; Yamamoto Y; Nishiyama Y
Ann Nucl Med; 2017 Jan; 31(1):63-70. PubMed ID: 27679399
[TBL] [Abstract][Full Text] [Related]
3. Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma.
Ito K; Yokoyama J; Miyata Y; Toyohara J; Okasaki M; Minamimoto R; Morooka M; Ishiwata K; Kubota K
Nucl Med Commun; 2015 Mar; 36(3):219-25. PubMed ID: 25369751
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study.
Hotta M; Minamimoto R; Yamada K; Nohara K; Soma D; Nakajima K; Toyohara J; Takase K
EJNMMI Res; 2019 Jan; 9(1):10. PubMed ID: 30701347
[TBL] [Abstract][Full Text] [Related]
6. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
7. Interim 4'-[methyl-
Mitamura K; Norikane T; Yamamoto Y; Fujimoto K; Takami Y; Hoshikawa H; Toyohara J; Nishiyama Y
EJNMMI Res; 2021 Feb; 11(1):13. PubMed ID: 33566186
[TBL] [Abstract][Full Text] [Related]
8.
Minamimoto R; Takeda Y; Hotta M; Toyohara J; Nakajima K; Naka G; Sugiyama H
EJNMMI Res; 2019 Jan; 9(1):4. PubMed ID: 30649637
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of
Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
12. 4'-[methyl-
Fukuda Y; Yamamoto Y; Mitamura K; Ishikawa R; Asano E; Toyohara J; Norikane T; Nishiyama Y
Ann Nucl Med; 2019 Nov; 33(11):822-827. PubMed ID: 31401773
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
14.
Lee S; Choi Y; Park G; Jo S; Lee SS; Park J; Shim HK
Technol Cancer Res Treat; 2021; 20():15330338211024655. PubMed ID: 34227434
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
16. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
17. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
19.
Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
